Institute for Health and Care Excellence (NICE) has today published
its Final Appraisal Determination on the use of
brodalumab (Kyntheum) for severe psoriasis in England and Wales.
is recommended to treat severe psoriasis, where people have not had adequate
results from conventional systemic treatments, or cannot take
them. NICE expects to publish its final and full guidance on the use of
brodalumab in March 2018, but the FAD is a good indication of what the final
decision will be.
blocks the activity of interleukin 17A (IL-17A), a chemical ’messenger’ in the
immune system that signals other cells to cause inflammation. In people with
psoriasis the immune system is overactive and creates too much inflammation,
which leads to the development of psoriasis symptoms. By blocking IL-17A,
Kyntheum aims to prevent some of that inflammation from occurring, leading to
an improvement in psoriasis for some people who take it. Other biologic
medications that block the activity of IL-17A, called Cosentyx (secukinumab) and Taltz (ixekizumab) are
currently available for people with severe psoriasis.
We will be publishing more information on brodalumab
(Kyntheum) for psoriasis soon. In the meantime, please get in touch with us if you have any questions.